Crizotinib, cabozantinib, tepotinib, capmatinib, amivantamab and savolitinib are the noted CDs evaluated for MET mutated anti-NSCLC therapy [159, 160]. The gene discussed is MET; the disease is non-small cell lung carcinoma.